 | • レポートコード：GIR-2104Z09714 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、重症筋無力症のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。重症筋無力症の種類別市場規模（薬物治療、迅速免疫療法）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・重症筋無力症の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Takeda、F. Hoffmann-La Roche、CSL Behring、Grifols、Alexion Pharmaceutical、Avadel Pharmaceuticals、Baxter International、Novartis、Bausch Health、Takeda Pharmaceutical Company ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：薬物治療、迅速免疫療法 ・用途別分析2016年-2026年：病院、診療所、その他 ・重症筋無力症の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・重症筋無力症のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・重症筋無力症のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・重症筋無力症の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・重症筋無力症の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Myasthenia Gravis market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Myasthenia Gravis size is estimated to be USD 1651.8 million in 2025 from USD 1130.2 million in 2019, with a change XX% between 2019 and 2020. The global Myasthenia Gravis market size is expected to grow at a CAGR of 10.0% for the next five years.
Market segmentation
Myasthenia Gravis market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Drug Treatment
Rapid Immunotherapies
Market segment by Application, can be divided into
Hospitals
Clinics
Other
Market segment by players, this report covers
Takeda
F. Hoffmann-La Roche
CSL Behring
Grifols
Alexion Pharmaceutical
Avadel Pharmaceuticals
Baxter International
Novartis
Bausch Health
Takeda Pharmaceutical Company
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Myasthenia Gravis
1.2 Classification of Myasthenia Gravis by Type
1.2.1 Overview: Global Myasthenia Gravis Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Myasthenia Gravis Revenue Market Share by Type in 2020
1.2.3 Drug Treatment
1.2.4 Rapid Immunotherapies
1.3 Global Myasthenia Gravis Market by Application
1.3.1 Overview: Global Myasthenia Gravis Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Myasthenia Gravis Market Size & Forecast
1.5 Global Myasthenia Gravis Market Size and Forecast by Region
1.5.1 Global Myasthenia Gravis Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Myasthenia Gravis Market Size by Region, (2016-2021)
1.5.3 North America Myasthenia Gravis Market Size and Prospect (2016-2026)
1.5.4 Europe Myasthenia Gravis Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Myasthenia Gravis Market Size and Prospect (2016-2026)
1.5.6 South America Myasthenia Gravis Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Myasthenia Gravis Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Myasthenia Gravis Market Drivers
1.6.2 Myasthenia Gravis Market Restraints
1.6.3 Myasthenia Gravis Trends Analysis
2 Company Profiles
2.1 Takeda
2.1.1 Takeda Details
2.1.2 Takeda Major Business
2.1.3 Takeda Myasthenia Gravis Product and Solutions
2.1.4 Takeda Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Takeda Recent Developments and Future Plans
2.2 F. Hoffmann-La Roche
2.2.1 F. Hoffmann-La Roche Details
2.2.2 F. Hoffmann-La Roche Major Business
2.2.3 F. Hoffmann-La Roche Myasthenia Gravis Product and Solutions
2.2.4 F. Hoffmann-La Roche Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.3 CSL Behring
2.3.1 CSL Behring Details
2.3.2 CSL Behring Major Business
2.3.3 CSL Behring Myasthenia Gravis Product and Solutions
2.3.4 CSL Behring Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 CSL Behring Recent Developments and Future Plans
2.4 Grifols
2.4.1 Grifols Details
2.4.2 Grifols Major Business
2.4.3 Grifols Myasthenia Gravis Product and Solutions
2.4.4 Grifols Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Grifols Recent Developments and Future Plans
2.5 Alexion Pharmaceutical
2.5.1 Alexion Pharmaceutical Details
2.5.2 Alexion Pharmaceutical Major Business
2.5.3 Alexion Pharmaceutical Myasthenia Gravis Product and Solutions
2.5.4 Alexion Pharmaceutical Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Alexion Pharmaceutical Recent Developments and Future Plans
2.6 Avadel Pharmaceuticals
2.6.1 Avadel Pharmaceuticals Details
2.6.2 Avadel Pharmaceuticals Major Business
2.6.3 Avadel Pharmaceuticals Myasthenia Gravis Product and Solutions
2.6.4 Avadel Pharmaceuticals Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Avadel Pharmaceuticals Recent Developments and Future Plans
2.7 Baxter International
2.7.1 Baxter International Details
2.7.2 Baxter International Major Business
2.7.3 Baxter International Myasthenia Gravis Product and Solutions
2.7.4 Baxter International Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Baxter International Recent Developments and Future Plans
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Myasthenia Gravis Product and Solutions
2.8.4 Novartis Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Novartis Recent Developments and Future Plans
2.9 Bausch Health
2.9.1 Bausch Health Details
2.9.2 Bausch Health Major Business
2.9.3 Bausch Health Myasthenia Gravis Product and Solutions
2.9.4 Bausch Health Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Bausch Health Recent Developments and Future Plans
2.10 Takeda Pharmaceutical Company
2.10.1 Takeda Pharmaceutical Company Details
2.10.2 Takeda Pharmaceutical Company Major Business
2.10.3 Takeda Pharmaceutical Company Myasthenia Gravis Product and Solutions
2.10.4 Takeda Pharmaceutical Company Myasthenia Gravis Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Takeda Pharmaceutical Company Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Myasthenia Gravis Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Myasthenia Gravis Players Market Share
3.2.2 Top 10 Myasthenia Gravis Players Market Share
3.2.3 Market Competition Trend
3.3 Myasthenia Gravis Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Myasthenia Gravis Revenue and Market Share by Type (2016-2021)
4.2 Global Myasthenia Gravis Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Myasthenia Gravis Revenue Market Share by Application (2016-2021)
5.2 Myasthenia Gravis Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Myasthenia Gravis Revenue by Type (2016-2026)
6.2 North America Myasthenia Gravis Revenue by Application (2016-2026)
6.3 North America Myasthenia Gravis Market Size by Country
6.3.1 North America Myasthenia Gravis Revenue by Country (2016-2026)
6.3.2 United States Myasthenia Gravis Market Size and Forecast (2016-2026)
6.3.3 Canada Myasthenia Gravis Market Size and Forecast (2016-2026)
6.3.4 Mexico Myasthenia Gravis Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Myasthenia Gravis Revenue by Type (2016-2026)
7.2 Europe Myasthenia Gravis Revenue by Application (2016-2026)
7.3 Europe Myasthenia Gravis Market Size by Country
7.3.1 Europe Myasthenia Gravis Revenue by Country (2016-2026)
7.3.2 Germany Myasthenia Gravis Market Size and Forecast (2016-2026)
7.3.3 France Myasthenia Gravis Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Myasthenia Gravis Market Size and Forecast (2016-2026)
7.3.5 Russia Myasthenia Gravis Market Size and Forecast (2016-2026)
7.3.6 Italy Myasthenia Gravis Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Myasthenia Gravis Revenue by Type (2016-2026)
8.2 Asia-Pacific Myasthenia Gravis Revenue by Application (2016-2026)
8.3 Asia-Pacific Myasthenia Gravis Market Size by Region
8.3.1 Asia-Pacific Myasthenia Gravis Revenue by Region (2016-2026)
8.3.2 China Myasthenia Gravis Market Size and Forecast (2016-2026)
8.3.3 Japan Myasthenia Gravis Market Size and Forecast (2016-2026)
8.3.4 South Korea Myasthenia Gravis Market Size and Forecast (2016-2026)
8.3.5 India Myasthenia Gravis Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Myasthenia Gravis Market Size and Forecast (2016-2026)
8.3.7 Australia Myasthenia Gravis Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Myasthenia Gravis Revenue by Type (2016-2026)
9.2 South America Myasthenia Gravis Revenue by Application (2016-2026)
9.3 South America Myasthenia Gravis Market Size by Country
9.3.1 South America Myasthenia Gravis Revenue by Country (2016-2026)
9.3.2 Brazil Myasthenia Gravis Market Size and Forecast (2016-2026)
9.3.3 Argentina Myasthenia Gravis Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Myasthenia Gravis Revenue by Type (2016-2026)
10.2 Middle East & Africa Myasthenia Gravis Revenue by Application (2016-2026)
10.3 Middle East & Africa Myasthenia Gravis Market Size by Country
10.3.1 Middle East & Africa Myasthenia Gravis Revenue by Country (2016-2026)
10.3.2 Turkey Myasthenia Gravis Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Myasthenia Gravis Market Size and Forecast (2016-2026)
10.3.4 UAE Myasthenia Gravis Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Myasthenia Gravis Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Myasthenia Gravis Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Myasthenia Gravis Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Myasthenia Gravis Revenue (USD Million) by Region (2016-2021)
Table 5. Global Myasthenia Gravis Revenue Market Share by Region (2021-2026)
Table 6. Takeda Corporate Information, Head Office, and Major Competitors
Table 7. Takeda Major Business
Table 8. Takeda Myasthenia Gravis Product and Solutions
Table 9. Takeda Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 11. F. Hoffmann-La Roche Major Business
Table 12. F. Hoffmann-La Roche Myasthenia Gravis Product and Solutions
Table 13. F. Hoffmann-La Roche Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. CSL Behring Corporate Information, Head Office, and Major Competitors
Table 15. CSL Behring Major Business
Table 16. CSL Behring Myasthenia Gravis Product and Solutions
Table 17. CSL Behring Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Grifols Corporate Information, Head Office, and Major Competitors
Table 19. Grifols Major Business
Table 20. Grifols Myasthenia Gravis Product and Solutions
Table 21. Grifols Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Alexion Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 23. Alexion Pharmaceutical Major Business
Table 24. Alexion Pharmaceutical Myasthenia Gravis Product and Solutions
Table 25. Alexion Pharmaceutical Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Avadel Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Avadel Pharmaceuticals Major Business
Table 28. Avadel Pharmaceuticals Myasthenia Gravis Product and Solutions
Table 29. Avadel Pharmaceuticals Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Baxter International Corporate Information, Head Office, and Major Competitors
Table 31. Baxter International Major Business
Table 32. Baxter International Myasthenia Gravis Product and Solutions
Table 33. Baxter International Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Novartis Corporate Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Myasthenia Gravis Product and Solutions
Table 37. Novartis Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 39. Bausch Health Major Business
Table 40. Bausch Health Myasthenia Gravis Product and Solutions
Table 41. Bausch Health Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Takeda Pharmaceutical Company Corporate Information, Head Office, and Major Competitors
Table 43. Takeda Pharmaceutical Company Major Business
Table 44. Takeda Pharmaceutical Company Myasthenia Gravis Product and Solutions
Table 45. Takeda Pharmaceutical Company Myasthenia Gravis Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Global Myasthenia Gravis Revenue (USD Million) by Players (2019-2021)
Table 47. Global Myasthenia Gravis Revenue Share by Players (2019-2021)
Table 48. Breakdown of Myasthenia Gravis by Company Type (Tier 1, Tier 2 and Tier 3)
Table 49. Myasthenia Gravis Players Head Office, Products and Services Provided
Table 50. Myasthenia Gravis Mergers & Acquisitions in the Past Five Years
Table 51. Myasthenia Gravis New Entrants and Expansion Plans
Table 52. Global Myasthenia Gravis Revenue (USD Million) by Type (2016-2021)
Table 53. Global Myasthenia Gravis Revenue Share by Type (2016-2021)
Table 54. Global Myasthenia Gravis Revenue Forecast by Type (2021-2026)
Table 55. Global Myasthenia Gravis Revenue by Application (2016-2021)
Table 56. Global Myasthenia Gravis Revenue Forecast by Application (2021-2026)
Table 57. North America Myasthenia Gravis Revenue by Type (2016-2021) & (USD Million)
Table 58. North America Myasthenia Gravis Revenue by Type (2021-2026) & (USD Million)
Table 59. North America Myasthenia Gravis Revenue by Application (2016-2021) & (USD Million)
Table 60. North America Myasthenia Gravis Revenue by Application (2021-2026) & (USD Million)
Table 61. North America Myasthenia Gravis Revenue by Country (2016-2021) & (USD Million)
Table 62. North America Myasthenia Gravis Revenue by Country (2021-2026) & (USD Million)
Table 63. Europe Myasthenia Gravis Revenue by Type (2016-2021) & (USD Million)
Table 64. Europe Myasthenia Gravis Revenue by Type (2021-2026) & (USD Million)
Table 65. Europe Myasthenia Gravis Revenue by Application (2016-2021) & (USD Million)
Table 66. Europe Myasthenia Gravis Revenue by Application (2021-2026) & (USD Million)
Table 67. Europe Myasthenia Gravis Revenue by Country (2016-2021) & (USD Million)
Table 68. Europe Myasthenia Gravis Revenue by Country (2021-2026) & (USD Million)
Table 69. Asia-Pacific Myasthenia Gravis Revenue by Type (2016-2021) & (USD Million)
Table 70. Asia-Pacific Myasthenia Gravis Revenue by Type (2021-2026) & (USD Million)
Table 71. Asia-Pacific Myasthenia Gravis Revenue by Application (2016-2021) & (USD Million)
Table 72. Asia-Pacific Myasthenia Gravis Revenue by Application (2021-2026) & (USD Million)
Table 73. Asia-Pacific Myasthenia Gravis Revenue by Region (2016-2021) & (USD Million)
Table 74. Asia-Pacific Myasthenia Gravis Revenue by Region (2021-2026) & (USD Million)
Table 75. South America Myasthenia Gravis Revenue by Type (2016-2021) & (USD Million)
Table 76. South America Myasthenia Gravis Revenue by Type (2021-2026) & (USD Million)
Table 77. South America Myasthenia Gravis Revenue by Application (2016-2021) & (USD Million)
Table 78. South America Myasthenia Gravis Revenue by Application (2021-2026) & (USD Million)
Table 79. South America Myasthenia Gravis Revenue by Country (2016-2021) & (USD Million)
Table 80. South America Myasthenia Gravis Revenue by Country (2021-2026) & (USD Million)
Table 81. Middle East & Africa Myasthenia Gravis Revenue by Type (2016-2021) & (USD Million)
Table 82. Middle East & Africa Myasthenia Gravis Revenue by Type (2021-2026) & (USD Million)
Table 83. Middle East & Africa Myasthenia Gravis Revenue by Application (2016-2021) & (USD Million)
Table 84. Middle East & Africa Myasthenia Gravis Revenue by Application (2021-2026) & (USD Million)
Table 85. Middle East & Africa Myasthenia Gravis Revenue by Country (2016-2021) & (USD Million)
Table 86. Middle East & Africa Myasthenia Gravis Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Myasthenia Gravis Picture
Figure 2. Global Myasthenia Gravis Revenue Market Share by Type in 2020
Figure 3. Drug Treatment
Figure 4. Rapid Immunotherapies
Figure 5. Myasthenia Gravis Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Other Picture
Figure 9. Global Myasthenia Gravis Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Myasthenia Gravis Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Myasthenia Gravis Revenue Market Share by Region (2016-2026)
Figure 12. Global Myasthenia Gravis Revenue Market Share by Region in 2020
Figure 13. North America Myasthenia Gravis Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Myasthenia Gravis Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Myasthenia Gravis Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Myasthenia Gravis Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Myasthenia Gravis Market Drivers
Figure 18. Myasthenia Gravis Market Restraints
Figure 19. Myasthenia Gravis Market Trends
Figure 20. Takeda Recent Developments and Future Plans
Figure 21. F. Hoffmann-La Roche Recent Developments and Future Plans
Figure 22. CSL Behring Recent Developments and Future Plans
Figure 23. Grifols Recent Developments and Future Plans
Figure 24. Alexion Pharmaceutical Recent Developments and Future Plans
Figure 25. Avadel Pharmaceuticals Recent Developments and Future Plans
Figure 26. Baxter International Recent Developments and Future Plans
Figure 27. Novartis Recent Developments and Future Plans
Figure 28. Bausch Health Recent Developments and Future Plans
Figure 29. Takeda Pharmaceutical Company Recent Developments and Future Plans
Figure 31. Global Myasthenia Gravis Revenue Share by Players in 2020
Figure 32. Myasthenia Gravis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Myasthenia Gravis Revenue Market Share in 2020
Figure 34. Global Top 10 Players Myasthenia Gravis Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Myasthenia Gravis Revenue Share by Type in 2020
Figure 37. Global Myasthenia Gravis Market Share Forecast by Type (2021-2026)
Figure 38. Global Myasthenia Gravis Revenue Share by Application in 2020
Figure 39. Global Myasthenia Gravis Market Share Forecast by Application (2021-2026)
Figure 40. North America Myasthenia Gravis Sales Market Share by Type (2016-2026)
Figure 41. North America Myasthenia Gravis Sales Market Share by Application (2016-2026)
Figure 42. North America Myasthenia Gravis Revenue Market Share by Country (2016-2026)
Figure 43. United States Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Myasthenia Gravis Sales Market Share by Type (2016-2026)
Figure 47. Europe Myasthenia Gravis Sales Market Share by Application (2016-2026)
Figure 48. Europe Myasthenia Gravis Revenue Market Share by Country (2016-2026)
Figure 49. Germany Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Myasthenia Gravis Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Myasthenia Gravis Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Myasthenia Gravis Revenue Market Share by Region (2016-2026)
Figure 57. China Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Myasthenia Gravis Sales Market Share by Type (2016-2026)
Figure 64. South America Myasthenia Gravis Sales Market Share by Application (2016-2026)
Figure 65. South America Myasthenia Gravis Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Myasthenia Gravis Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Myasthenia Gravis Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Myasthenia Gravis Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Myasthenia Gravis Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source
世界の重症筋無力症市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myasthenia Gravis Market The global Myasthenia Gravis market size is projected to reach US$ 2212 million by 2026, from US$ 1098.4 million in 2019, at a CAGR of 10.4% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report…- 世界の重症筋無力症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Myasthenia Gravis Treatment Market The global Myasthenia Gravis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity…
- 世界の重症筋無力症市場規模・現状・予測（2021年-2027年） Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. The most commonly affected muscles are those of the eyes, face, and swallowing. It can result in double vision, drooping eyelids, trouble talking, and trouble walking. Onset can be …
- 世界の重症筋無力症治療薬市場規模・現状・予測（2021年-2027年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- 世界の重症筋無力症治療市場規模・現状・予測（2021年-2027年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …